| Topic | Key finding | Evidence / source |
|---|---|---|
| Identity / identifiers | Chung-Jansen syndrome (CHUJANS), also called DIDOD syndrome; OMIM disease identifier reported as **#617991**. Disease-level identifiers beyond OMIM (e.g., MONDO, HPO set) should be treated as **needing database validation** if not independently verified. | 2023 cohort paper states CHUJANS, OMIM #617991; PHIP gene OMIM *612870 (pqac-00000001, pqac-00000002) |
| Causal gene and mechanism | Primary causal gene is **PHIP** (pleckstrin homology domain interacting protein). Current understanding supports **PHIP haploinsufficiency** as the main disease mechanism; variant classes include truncating, missense, splice, and larger deletions. | Kampmeier et al., 2023, *Front Cell Dev Biol*, DOI: https://doi.org/10.3389/fcell.2022.1020609 (pqac-00000002) |
| Inheritance | Usually **autosomal dominant** with many **de novo** cases, but inherited cases from **mildly affected parents** are documented, indicating **variable expressivity** and likely reduced/variable penetrance in some families. In the 23-person 2023 cohort, inheritance was seen in multiple maternal or paternal transmissions. | 2023 cohort summary and segregation analysis (Sanger/qPCR/FISH) (pqac-00000001, pqac-00000002) |
| Strongest 2023 phenotype frequencies | In 23 newly reported individuals: developmental delay **22/23**, learning disability/intellectual disability **22/23**, behavioral abnormalities **20/23**, weight problems **13/23**, and characteristic craniofacial features **23/23**; cohort included **13 males / 10 females**. Facial pattern included large ears/earlobes, prominent eyebrows, anteverted nares, and long philtrum. | Kampmeier et al., 2023, DOI: https://doi.org/10.3389/fcell.2022.1020609 (pqac-00000001, pqac-00000002, pqac-00000003) |
| Clinical course / phenotype interpretation | Neurodevelopmental and behavioral features begin in childhood; obesity/overweight is common but variably penetrant and may emerge from childhood to puberty. Behavioral issues can include impulsivity, aggression, anxiety, hyperactivity, and autism-spectrum features; regular follow-up into adulthood was recommended. | 2023 cohort interpretation (pqac-00000000) |
| Molecular evidence | PHIP has both **cytoplasmic** and **nuclear** functions. Functional data support obesity pathogenesis through impaired **POMC transcription** in the leptin-melanocortin pathway. Wild-type PHIP enhanced POMC transcription, whereas all tested PHIP mutants reduced it; some variants showed **dominant-negative** effects. Case variants also decreased the nuclear:cytoplasmic PHIP ratio (**p=0.004**). | Marenne et al., 2020, *Cell Metab*, DOI: https://doi.org/10.1016/j.cmet.2020.05.007 (pqac-00000008, pqac-00000009, pqac-00000013) |
| Obesity genetics signal | In severe childhood obesity sequencing analyses, **PHIP** showed an excess burden of very rare predicted deleterious variants; reported enrichment for obese cases had **p=4.58×10^-4** and **OR=2.4 [1.5–3.84]**. | Marenne et al., 2020, DOI: https://doi.org/10.1016/j.cmet.2020.05.007 (pqac-00000008) |
| Additional mechanistic biology | Published disease discussions also connect PHIP disruption with **replication fork stability / genome integrity** defects, although disease-specific pathway resolution remains incomplete. | 2023 disease cohort discussion (pqac-00000004) |
| Diagnostics | Diagnosis is currently based on **genetic testing** plus clinical evaluation. Methods reported include **microarray, gene panels, exome sequencing**, followed by **Sanger sequencing, qPCR, and FISH** for confirmation/segregation. PHIP should be considered on DD/ID/behavioral abnormality/obesity panels. Facial phenotyping tools such as **GestaltMatcher** may support recognition but are not standalone diagnostics. | Kampmeier et al., 2023, DOI: https://doi.org/10.3389/fcell.2022.1020609 (pqac-00000002, pqac-00000003, pqac-00000005) |
| Real-world implementation / registries | The main identified implementation resource is **Simons Searchlight** (**NCT01238250**), a recruiting, international, longitudinal **observational** registry collecting medical, behavioral, developmental, and genetic data from individuals with eligible neurodevelopmental genetic conditions, including PHIP-related disorders. It does **not** test treatments. | ClinicalTrials.gov NCT01238250 / Simons Searchlight (pqac-00000014, pqac-00000015) |
| Management / treatment | No disease-specific, evidence-based **disease-modifying therapy** or interventional trial was identified in the retrieved evidence. Current care is **multidisciplinary and phenotype-directed**: developmental/behavioral assessment, educational supports, obesity surveillance and management, and genetic counseling for families. | Derived from absence of interventional trial evidence plus cohort recommendations for follow-up (pqac-00000000, pqac-00000014, pqac-00000015) |
| Major evidence gaps | Population prevalence/incidence, validated survival data, disease-specific quality-of-life measures, penetrance estimates, genotype-phenotype correlations, standardized treatment algorithms, and validated MONDO/HPO identifier set remain **insufficiently defined** in the retrieved evidence. Disease-specific single-cell, spatial transcriptomic, proteomic, and metabolomic studies were not identified here. | Evidence gap synthesis from available cohort/mechanistic/registry sources (pqac-00000000, pqac-00000008, pqac-00000014) |


*Table: This table condenses the highest-yield disease knowledge-base facts for Chung-Jansen syndrome, including identifiers, genetics, phenotype frequencies, mechanism, diagnostics, management, and evidence gaps. It is designed as a compact reference for curation and downstream database entry.*